Prot #EVP-6124-015: A Randomized, Double-blind, Placebo-controlled, Parallel, 12-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects

Project: Research project

Project Details

StatusFinished
Effective start/end date3/1/133/1/16

Funding

  • FORUM Pharmaceuticals Inc. (Prot #EVP-6124-015)